We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+55.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7B
AUM Growth
+$1.73B
Cap. Flow
-$5.41M
Cap. Flow %
-0.08%
Top 10 Hldgs %
37.61%
Holding
156
New
40
Increased
17
Reduced
34
Closed
20

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$111M
2
BMY icon
Bristol-Myers Squibb
BMY
+$97.4M
3
GKOS icon
Glaukos
GKOS
+$94.2M
4
DHR icon
Danaher
DHR
+$91.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$77.7M

Top Sells

Rank Stock Value
1
AVDR
Avedro, Inc Common Stock
AVDR
+$96.3M
2
WMGI
Wright Medical Group Inc
WMGI
+$79.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$66.9M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$55.9M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.81%
2 Financials 1.53%
3 Miscellaneous 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
51
argenx
ARGX
$62.5B
$41.1M 0.59%
256,300
-54,100
-17% -$7.32M
TELA icon
52
TELA Bio
TELA
$48M
$39.2M 0.56%
+3,027,542
New +$37M
CRVS icon
53
Corvus Pharmaceuticals
CRVS
$1.07B
$36.8M 0.53%
6,767,584
– –
HARP
54
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$36.2M 0.52%
244,641
– –
ELV icon
55
Elevance Health
ELV
$91.1B
$32.2M 0.46%
106,600
-148,000
-58% -$40.7M
AMGN icon
56
Amgen
AMGN
$205B
$29.4M 0.42%
122,100
– –
HCA icon
57
HCA Healthcare
HCA
$92B
$28.1M 0.4%
+190,000
New +$25.5M
IQV icon
58
IQVIA
IQV
$44.7B
$27M 0.39%
175,000
– –
APLT
59
DELISTED
Applied Therapeutics
APLT
$26.9M 0.38%
+987,186
New +$16.9M
ZBH icon
60
Zimmer Biomet
ZBH
$18.7B
$26.7M 0.38%
+184,061
New +$25.4M
VRCA icon
61
Verrica Pharmaceuticals
VRCA
$78.5M
$23.5M 0.34%
147,973
– –
HLSQ
62
Tessera Defense and Homeland Security Inc.
HLSQ
$2.86M
$22.4M 0.32%
+1,218
New +$21M
SYRE icon
63
Spyre Therapeutics
SYRE
$7.98B
$21.9M 0.31%
114,621
– –
ZLAB icon
64
Zai Lab
ZLAB
$2.8B
$21.4M 0.31%
514,000
– –
GILD icon
65
Gilead Sciences
GILD
$181B
$21.2M 0.3%
326,100
– –
ALC icon
66
Alcon
ALC
$32.8B
$19.9M 0.28%
351,380
– –
SCPH
67
DELISTED
scPharmaceuticals
SCPH
$19.3M 0.28%
3,409,865
– –
BIIB icon
68
Biogen
BIIB
$32B
$19.1M 0.27%
64,500
+28,300
+78% +$7.85M
NVO
69
Novo Nordisk
NVO
$189B
$19.1M 0.27%
660,000
– –
AVTR icon
70
Avantor
AVTR
$10.5B
$18.4M 0.26%
+1,012,800
New +$16.1M
SVA
71
DELISTED
Sinovac Biotech, Ltd
SVA
$17.2M 0.24%
2,839,500
– –
XTNT icon
72
Xtant Medical Holdings
XTNT
$45M
$14.7M 0.21%
9,207,012
– –
ALPN
73
DELISTED
Alpine Immune Sciences Inc
ALPN
$14.1M 0.2%
3,670,955
– –
TECX
74
Tectonic Therapeutic
TECX
$555M
$12.8M 0.18%
52,892
+5,334
+11% +$1.03M
KALA icon
75
KALA BIO
KALA
$10.1M
$12.7M 0.18%
1,381
– –
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2019 Portfolio in Review

As of Q4 2019, OrbiMed held 156 positions worth $7B, up 33% from $5.27B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q4 2019 filing shows 40 new, 17 increased, 34 reduced and 20 closed positions. Its largest new stake was 89bio: 4,004,442 shares worth $105M. The largest sale was Avedro, Inc Common Stock, an estimated $96.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q4 2019 buy was 89bio: 4,004,442 shares worth $105M.
  • OrbiMed added most to Mirati Therapeutics, Inc. Common Stock in Q4 2019, an estimated $77.7M increase.
  • OrbiMed's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $66.9M.
  • OrbiMed fully exited Avedro, Inc Common Stock in Q4 2019, selling an estimated $96.3M.
  • OrbiMed's ten largest holdings make up 38% of its $7B portfolio in Q4 2019.
  • OrbiMed opened 40 new positions and closed 20 in Q4 2019.
  • OrbiMed's portfolio value rose 33% quarter-over-quarter to $7B.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.